#United Kingdom #Piramal Pharma #Korsch XM-12 #Morpeth

Piramal Pharma Solutions Boosts Its Formulation Capabilities with Korsch XM-12

Piramal Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO), has recently enhanced its formulation capabilities with the introduction of the state-of-the-art Korsch XM-12 bilayer tablet press at its facility in Morpeth, UK. This significant addition is set to bolster the company's ability to develop and manufacture high-quality pharmaceutical products.

Enhancing Production Efficiency

The acquisition of the Korsch XM-12 tablet press is a strategic move aimed at increasing the production of fixed-dose combinations and modified-release medicines. This advanced equipment provides the formulation development team with a critical tool that allows for more flexible production formats while ensuring precision and efficiency. Equipped for both single and bilayer tablet production, the XM-12 features advanced hygiene equipment, ensuring a secure and effective manufacturing process for highly active pharmaceutical ingredients. It also has special tooling that allows for quick changeovers, accommodating the varying demands of pharmaceutical production.

Frank Bugg, the General Manager of the Morpeth site, emphasized the importance of this new addition, stating, "The Korsch XM-12 will significantly enhance our production capabilities, allowing us to maintain high standards of quality and safety across all operations. We are committed to providing the best possible medicines to patients worldwide."

Commitment to Safety and Quality

Piramal Pharma Solutions has implemented comprehensive training protocols to ensure safe operation and the production of high-quality outputs with the XM-12. Understanding the complexity involved, the company has collaborated with Korsch to provide thorough training for all personnel, including researchers, operators, and maintenance teams. This training will be tailored to meet the unique needs of each role within the formulation team.

The training encompasses critical operational aspects such as the handling, cleaning, and maintenance of equipment, designed specifically for the dual-layer and single-layer functionalities. Each operator's and researcher's training will focus on practical skills while adhering to industry standards and Piramal’s stringent quality requirements.

Revolutionizing Pharmaceutical Manufacturing

The new Korsch XM-12 press represents a significant advancement in tablet manufacturing technology, allowing Piramal to produce superior tablets on a much larger scale. This increased capability not only ensures speed and accuracy in the production of pharmaceuticals but also maintains the flexibility necessary to adapt to the fast-evolving marketplace.

With this investment, Piramal Pharma Solutions is better equipped to provide innovative therapies while continuing to improve the quality of life for patients around the world. By enhancing its production capabilities, Piramal aims to reduce the disease burden globally and ensure that more patients have access to effective treatments. The XM-12 is central to this initiative, signifying a firm step toward elevating medicinal administration practices.

About Piramal Pharma Solutions

Piramal Pharma Solutions operates as a prominent CDMO, offering end-to-end development and manufacturing solutions throughout the drug lifecycle. With a vast integrated network of facilities in North America, Europe, and Asia, the company provides an extensive array of services, from drug discovery to commercial supply of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. Specializing in potent active pharmaceuticals and complex generics, Piramal Pharma Solutions is dedicated to delivering tailored solutions to meet diverse client needs.

For more information about Piramal Pharma Solutions and its cutting-edge operations, visit their official website and explore their varied offerings. The expansion of the Morpeth facility with the Korsch XM-12 is just one of the many steps the firm is taking toward innovation in the pharmaceutical industry.